Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (28)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers

    Cancers, Vol. 14, Núm. 18

  3. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  2. Genomic correlates of dna damage in breast cancer subtypes

    Cancers, Vol. 13, Núm. 9

  3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

    Biomedicine and Pharmacotherapy, Vol. 144

  4. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  5. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20

  3. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21

  4. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  5. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

    Breast Cancer Research, Vol. 22, Núm. 1

  6. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  7. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

  8. Proteolysis targeting chimeras (PROTACs) in cancer therapy

    Journal of Experimental and Clinical Cancer Research, Vol. 39, Núm. 1

  9. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond

    Trends in Cancer, Vol. 6, Núm. 2, pp. 130-146

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1